Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reteplase vs alteplase for acute ischemic stroke within 4.5 hours
CTR20213294Phase 3Completed
- Sponsor
- Shandong Ahua Biological Pharmaceutical
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Ruitongli in ischemic stroke, sponsored by Shandong Ahua Biological Pharmaceutical. Started Feb 2022; status: completed.
02
Drugs
Ruitongli
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20213294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213294.